Silence Therapeutics Investor Relations Material

Silence Therapeutics plc is a biotechnology company that focuses on the discovery and development of therapeutic molecules using RNA interference (RNAi) technology. The company’s proprietary mRNAi GOLD platform is designed to develop short interfering RNA (siRNA) therapies that target and silence specific genes associated with various diseases, particularly in the liver. Silence Therapeutics is involved in developing treatments for cardiovascular conditions, hematological disorders, and rare diseases. Their leading product candidates include Zerlasiran (SLN360) for cardiovascular disease and Divesiran (SLN124) for hematological conditions. Silence Therapeutics plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.